NICE chief: NHS faces 'startling costs' from new treatments

Sir Andrew Dillon

The NHS faces a “material challenge” to fund new personalised drugs and deal with the “startling costs” of new medical technology, says the chief executive of the National Institute for Health and Care Excellence.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here